QDEL

QuidelOrtho Corporation provides in vitro diagnostics, developing and manufacturing intelligent solutions. The Company specializes in immunoassay and molecular testing, clinical chemistry and transfusion medicine. Its business units include labs, molecular diagnostics, point of care and transfusion medicine. Under the labs business unit, its product categories include virology & bioassays, specialty products, VITROS platform and immunodiagnostics. Under the molecular diagnostics business unit, its product categories include Lyra, Solana and Savanna. Under the point of care business unit, its product categories include rapid immunoassay and cardiometabolic immunoassay. Under the transfusion medicine business unit, its product categories include immunohematology and donor screening. It provides diagnostic testing solutions under various brand names, including AdenoPlus, BIOVUE, FreshCells, InflammaDry, Lyra, MeterPro, MicroVue, Ortho, Ortho Clinical Diagnostics and Ortho Optix.

Wall Street analysts forecast QDEL stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for QDEL is 34.60 USD with a low forecast of 22.00 USD and a high forecast of 62.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

QuidelOrtho Corp revenue for the last quarter amounts to 699.90M USD, decreased -3.74 % YoY.

QuidelOrtho Corp. EPS for the last quarter amounts to -10.78 USD, increased 3493.33 % YoY.

QuidelOrtho Corp (QDEL) has 6600 emplpoyees as of December 16 2025.

Today QDEL has the market capitalization of 1.97B USD.